QUINJA (IODOQUINOL AND ALOE POLYSACCHARIDE) GEL [NOVUM PHARMA, LLC]

QUINJA (IODOQUINOL AND ALOE POLYSACCHARIDE) GEL [NOVUM PHARMA, LLC]
PDF | XML

NDC 69646-716-01, 69646-716-02, 69646-716-10, 69646-716-11, 69646-716-60
Set ID a255163d-8b55-4f71-a630-cf7785eb7cb9
Category HUMAN PRESCRIPTION DRUG LABEL
Packager Novum Pharma, LLC
Generic Name
Product Class
Product Number
Application Number
  • SPL UNCLASSIFIED SECTION

    Prescribing Information

    QUINJA™ gel

    (1.25% iodoquinol and 1% aloe polysaccharides)

  • DESCRIPTION

    Each gram of QUINJA contains 1.25% (12.5 mg) Iodoquinol and 1% (10 mg) Aloe Polysaccharides. Other ingredients: Purified Water, Carbomer 980, Magnesium Aluminum Silicate, PEG-20 Methyl Glucose Ether, Aminomethyl Propanol 95, Biopeptide, Propylene Glycol, Glycerine, SDA Alcohol 40 B, Benzyl Alcohol, Trolamine, FD&C Blue #1 and D&C Yellow #10.

    Iodoquinol

    Iodoquinol is an antifungal and antibacterial agent. Chemically, Iodoquinol is [5,7-diiodo-8-quinolinol] with the molecular formula (C9H5I2NO) and is represented by the following structural formula:

    structural formula for Iodoquinol

    Aloe Polysaccharide

    The Aloe Polysaccharide in QUINJA is a patented mixture of acetylated mannan aloe polysaccharide mixture with average molecular weights of 80 and 1300 kDa (CAS 89191- 46-8). Each purified acetylated mannan polysaccharide of specific molecular weight range and average is composed of the same repeating subunits shown below (where m is mannose, n is galactose and p is glucose monomers):

    Aloe Polysaccharide

  • INDICATIONS AND USAGE

    Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: “Possibly” Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis; intertrigo. Final classification of the less-than- effective indications requires further investigation.

  • CONTRAINDICATIONS

    QUINJA is contraindicated in those patients with a history of hypersensitivity to any components of the preparation.

  • WARNINGS AND PRECAUTIONS

    For external use only. Keep away from eyes. If irritation develops, the use of QUINJA should be discontinued and appropriate therapy instituted. Some discoloration of the skin, hair and fabrics may occur, but can be removed with normal cleansing and laundry. Not intended for use on infants or under diapers or occlusive dressings.

    Iodoquinol may be absorbed through the skin and interfere with thyroid function tests. If such tests are contemplated, wait at least one month after discontinuance of therapy to perform these tests. The ferric chloride test for phenylketonuria (PKU) can yield a false positive result if Iodoquinol is present in the diaper or urine. Prolonged use may result in over- growth of non-susceptible organisms requiring appropriate therapy. Keep out of reach of children.

    Carcinogenesis, Mutagenisis and Impairment of Fertility:

     Long-term animal studies have not been performed to evaluate the carcinogenic potential of the effect on fertility of Iodoquinol. Mutagenicity studies have not been performed with Iodoquinol.

    Pregnancy Category C:

    Animal reproductive studies have not been conducted with QUINJA. It is not known whether QUINJA can cause fetal harm when administered to pregnant women or can affect reproductive capacity. QUINJA should be given to pregnant women only if clearly needed.

    Nursing Mothers:

    It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when QUINJA is administered to a nursing woman.

    Pediatric Use:

    Safety and effectiveness in pediatric patients under the age of 12 have not been established.

  • ADVERSE REACTIONS

    Adverse reactions from topical use of QUINJA is expected to be low when used as directed, due to low concentration of Iodoquinol present in this topical gel.

    To achieve the equivalent of a common daily oral dose of nearly 2,000 mg Iodoquinol, one will need to use more than 2 full tubes of 60 g QUINJA in a single application. Adverse reactions from oral form of Iodoquinol (nearly 2,000 mg daily) have been reported: various forms of skin eruptions, hives, itching, nausea, vomiting, abdominal cramps, diarrhea, anusitis, fever, chills, headache, vertigo and enlargement of thyroid.

  • DOSAGE AND ADMINISTRATION

    Apply to affected areas 3-4 times daily or as directed by a physician. Follow your physician’s directions regarding length of treatment after symptoms resolve.

  • HOW SUPPLIED

    NDC # 69646-716-60……60 gram gel tube
    NDC # 69646-716-01……1 gram gel individual pack
    NDC # 69646-716-10……10-count carton of 1 gram gel sample packs – not for resale
    NDC # 69646-716-02…… 2 gram gel individual tube
    NDC # 69646-716-11…… 10-count carton of 2 gram gel sample tubes – not for resale

    Each 1 gram gel pack contains multiple doses depending on the surface area treated.

    Each 2 gram gel tube contains multiple doses depending on the surface area treated.

  • STORAGE

    Store at 20°C to 25°C (68°F to 77°F), excursions
    permitted between 15°C and 30°C (between 59°F and 86°F).
    Brief exposure to temperatures up to 40°C (104°F) may be tolerated provided the mean kinetic
    temperature does not exceed 25°C (77°F); however, such exposure should be minimized.

    Distributed by:
    Novum Pharma, LLC
    Chicago, IL 60606

    ©2018 Novum Pharma, LLC. All rights reserved. QUI-022018-003

  • PRINCIPAL DISPLAY PANEL

    NDC 69646-716-60
    QUINJA gel
    1.25% iodoquinol 1% aloe polysaccharides
    Rx Only
    Net Wt. 60g

     NDC 69646-716-60
QUINJA gel
1.25% iodoquinol 1% aloe polysaccharides
Rx Only
Net Wt. 60g

  • INGREDIENTS AND APPEARANCE
    QUINJA 
    iodoquinol and aloe polysaccharide gel
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:69646-716
    Route of AdministrationTOPICAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    IODOQUINOL (UNII: 63W7IE88K8) (IODOQUINOL - UNII:63W7IE88K8) IODOQUINOL12.5 mg  in 1 g
    ALOE VERA LEAF (UNII: ZY81Z83H0X) (ALOE VERA LEAF - UNII:ZY81Z83H0X) ALOE VERA LEAF10 mg  in 1 g
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    CARBOMER HOMOPOLYMER TYPE C (ALLYL PENTAERYTHRITOL CROSSLINKED) (UNII: 4Q93RCW27E)  
    MAGNESIUM ALUMINUM SILICATE (UNII: 6M3P64V0NC)  
    PROPYLENE GLYCOL (UNII: 6DC9Q167V3)  
    GLYCERIN (UNII: PDC6A3C0OX)  
    ALCOHOL (UNII: 3K9958V90M)  
    BENZYL ALCOHOL (UNII: LKG8494WBH)  
    TROLAMINE (UNII: 9O3K93S3TK)  
    FD&C BLUE NO. 1 (UNII: H3R47K3TBD)  
    D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:69646-716-1010 in 1 CARTON07/20/2017
    1NDC:69646-716-011 g in 1 PACKET; Type 0: Not a Combination Product
    2NDC:69646-716-011 g in 1 PACKET; Type 0: Not a Combination Product07/20/2017
    3NDC:69646-716-022 g in 1 TUBE; Type 0: Not a Combination Product03/16/2018
    4NDC:69646-716-1110 in 1 CARTON03/16/2018
    4NDC:69646-716-022 g in 1 TUBE; Type 0: Not a Combination Product
    5NDC:69646-716-6060 g in 1 TUBE; Type 0: Not a Combination Product07/20/2017
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    UNAPPROVED DRUG OTHER07/20/2017
    Labeler - Novum Pharma, LLC (079736743)